CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Clene Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$3.29+0.19 (+6.13%)

Close on Oct 19, 2026

Market cap: $40.74M
P/E (TTM): –
Dividend yield: –

Clene Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	0.20	0.34	0.65	0.47	0.72	0.21	–
Cost of Revenue	0.04	0.07	0.12	0.03	0.29	–	–
Gross Profit	0.16	0.27	0.53	0.45	0.43	–	–
Research & Development	14	20	27	32	28	15	9.56
General & Administrative	9.23	13	14	17	22	5.15	6.77
Operating Expenses	–	–	–	–	51	20	16
Total Costs & Expenses	23	33	41	49	51	–	–
Operating Income	-23	-33	-41	-48	-50	-20	-16
Interest Expense	2.68	4.06	4.56	3.30	0.87	0.95	0.09
Interest & Investment Income	0.22	0.87	1.39	0.23	–	–	–
Other Non-Operating Income	-3.09	-6.31	-8.96	18	40	1.34	0.18
Gain (Loss) on Sale of Assets	0	-0.15	0	–	–	–	–
Pretax Income	-26	-39	-50	-30	-10	-19	-16
Income Tax Expense	0	0	0	0	-0.43	0.41	–
Net Income incl. Noncontrolling Interests	–	–	–	–	-9.74	-19	-16
Net Income	-26	-39	-50	-30	-9.74	-19	-16
EPS (Basic)(per share)	-2.65	-5.67	-9.43	-9.20	-3.20	-22.00	-18.60
EPS (Diluted)(per share)	–	–	–	–	-3.20	-22.00	-18.60
Shares Outstanding (Basic, Weighted)(shares)	9.86	6.95	5.25	3.26	3.08	0.88	0.87
Shares Outstanding (Diluted, Weighted)(shares)	9.86	6.95	5.25	3.26	3.08	0.88	0.87
Net Interest Income	–	–	–	-3.30	-0.87	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 70.1%
Operating margin: -10432.0%
Net margin: -20059.9%
Return on equity, FY2025: 197.9%

Financial strength

Current ratio: 3.07
Debt to equity: -0.22
Debt to assets: 23.3%
Cash to current liabilities: 199.3%

Valuation

P/E ratio: –
Price to sales: 206.80
Price to book: –
Dividend yield: –